RDIF and Samruk-Kazyna sign memorandum to cooperate in fight against coronavirus

Press release, 17.07.2020

Moscow, July 17, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Samruk-Kazyna, Kazakhstan’s sovereign wealth fund, have signed a memorandum of cooperation to counteract coronavirus infection.

Under the memorandum, RDIF has already delivered the first batches of coronavirus drug Avifavir to the Republic of Kazakhstan. This is the first Russian drug approved to treat coronavirus infection and the world's first registered favipiravir-based drug against COVID-19 with clinically proven efficacy. Avifavir blocks the reproduction mechanisms of coronavirus, relieving symptoms and halving the treatment period compared to standard therapy. The efficacy has been proven in clinical trials held in 35 medical centers across Russia involving 330 patients with confirmed COVID-19.

RDIF and Samruk-Kazyna have also agreed to cooperate in clinical trials, procurement and production of a vaccine against coronavirus. In accordance with the memorandum, the parties will consider the possibility of obtaining the necessary certification in Kazakhstan for the first Russian vaccine against COVID-19 developed by the Gamaleya National Research Institute of Epidemiology and Microbiology to be supplied to the country or produced locally.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
“International cooperation is a key factor for the successful fight against the coronavirus pandemic. RDIF actively collaborates with Samruk-Kazyna to supply advanced Russian solutions against coronavirus to Kazakhstan. The country has already received 9,500 packages of Avifavir, the world's first registered favipiravir-based drug against coronavirus with clinically proven efficacy. We are confident that an effective fight against the current and future pandemics is only possible through joint global efforts”.

***

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at www.rdif.ru

For additional information contact:
Arseniy Palagin
Russian Direct Investment Fund
Press Secretary
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
E-mail: arseniy.palagin@rdif.ru

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler
Tel: +44 (0) 20 7796 4133